Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
From – Diagnostic Testing & Emerging Technologies
New research suggests that potential shifts might occur in diabetes-related testing, including potential increased use of…
From – Diagnostic Testing & Emerging Technologies
A simple blood test can accurately, noninvasively, and quickly diagnose heart disease, according to a study published in the…
From – Diagnostic Testing & Emerging Technologies
Patients at risk for tuberculosis (TB) infection should be assessed with newer tests, including interferon-gamma release assays (IGRAs) and molecular diagnostics, according to…